Skip to main content
H.R. 9418 119th Congress House

Access to Innovative Treatments Act of 2026

Official title: To amend title XVIII of the Social Security Act to provide a review process for adverse national coverage determinations with respect to drug coverage under the Medicare program.

Introduced: June 24, 2026 Introduced by: Nanette Diaz Barragán Democratic · California See on congress.gov
Health
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 24, 2026
Introduced in House
Jun 24, 2026
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

What's happening now June 24, 2026

Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

 Plain-English summary Congressional Research Service

Access to Innovative Treatments Act of 2026

This bill requires the Centers for Medicare & Medicaid Services (CMS) to review adverse national coverage determinations of drugs under Medicare within 30 days of receiving a request to do so.

Specifically, the CMS must review within 30 days any denials or limitations of coverage that are inconsistent with the drug's approval by the Food and Drug Administration (FDA). The bill's requirements do not apply if the CMS already conducted such a review within a two-year period.

The bill also prohibits the CMS from applying prior coverage determinations that were made for drugs before they were approved by the FDA if such determinations are inconsistent with the drug's approval.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Lobbying activity 5

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

Bodies those filers lobbied

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.

 Cosponsors 1
All 1 Republican 1
R
Joyce, John
Pennsylvania · Jun 24, 2026
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 9418: Access to Innovative Treatments Act of 2026. 119th Congress. Open America. https://openamerica.io/bill/119-HR-9418/
MLA
"H.R. 9418: Access to Innovative Treatments Act of 2026." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-HR-9418/.
Bluebook (legal)
H.R. 9418, 119th Cong. (2026), https://openamerica.io/bill/119-HR-9418/.
Markdown link
[H.R. 9418: Access to Innovative Treatments Act of 2026](https://openamerica.io/bill/119-HR-9418/)
Report a problem